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Introduction
Receptor-mediated gene transfer by molecular conjugates was first demonstrated over 10 years ago. 1 Since then a variety of nonviral gene delivery systems has been developed that use molecular conjugates to form a polyplex with DNA. [2] [3] [4] [5] Although able to mediate efficient gene delivery in vitro, there has been limited advancement in the development of this vector in recent years. Studies by Chowdhury et al 6 initially showed that gene delivery to the liver could be achieved by an asialo-orosomucoid (ASOR)/DNA polyplex at high efficiency when combined with a partial hepatectomy; however, there have been few reports documenting delivery to other organs in vivo. This is due in part to the complexity of this gene delivery vector and the number of components that are required to generate this system as a 'synthetic virus'.
At minimum, this gene delivery vector requires the use of the following components: (1) a targeting ligand; (2) a DNA-binding agent; (3) a component to mediate endosomal release or bypass; and (4) a gene containing construct, ie a plasmid. One of the more commonly used DNA-binding agents is the polycation, poly-l-lysine (PLL). [1] [2] [3] [4] [5] [6] This polyamine has been used in many size ranges from Ͻ20 amino groups to Ͼ1000 amino groups, with each aiding in gene delivery in the associated system. [1] [2] [3] [4] [5] [6] [7] The major functions of PLL in these systems is to bind to negatively charged DNA allowing for both the Correspondence: RJ Cristiano Received 11 November 1997; accepted 30 March 1998 attachment of protein or peptide components to the polyplex and to aid in the compaction of the DNA molecule. However, one of the problems associated with this strategy is that the resulting polyplex can aggregate due to neutralization of the charge on the DNA backbone. As a result, this requires the concentration of the polyplex components to be extremely dilute. [1] [2] [3] [4] [5] [6] [7] Compounding this problem is the inclusion of other important components into the polyplex such as the targeting ligand and the method by which the ligand is attached to the polyplex. Small peptides such as epidermal growth factor (EGF), as well as large proteins such as monoclonal antibodies have been used to mediate specific gene delivery. 5, 8 The inclusion of these components into the polyplex has required the use of several linking strategies to mediate coupling to PLL. These have ranged from using chemical manipulations such as water-soluble carbodiimides to utilizing the interaction between proteins such as the streptavidin/biotin linkage. 1, 2, 5, 9 When these components are used to form polyplexbased vectors, each imparts a different effect on the overall particle charge and as a result can have a further effect on particle size, particle stability and potentially lead to the interaction of the polyplex with other proteins such as complement. 10 As a result, the use of these polyplex systems has now required that these vectors be generated as 'pharmacological agents'. To achieve this, the factors involved in the formulation of the polyplexes must be characterized, as well as analyzing the changes in the physical properties of the polyplex during formation. Analysis of the literature shows conflicting as well as incomplete reports as to how protein/DNA polyplex formation occurs and what effects the components have on this process. To clarify some of the properties of this vector delivery system, we report here the analysis of the contribution of PLL size, a ligand such as epidermal growth factor, and coupling proteins such as streptavidin to particle size, particle charge, and gene delivery and provide some criteria for generating stable protein/DNA polyplexes for efficient gene delivery.
Results
The effect of PLL chain length on particle size and charge Poly-l-lysine is one of the more commonly used polycations for DNA compaction; however, there are contradictions in the literature as to what size results in optimum polyplex formation. [1] [2] [3] [4] [5] [6] [7] [8] 11 To answer this question, we tested the effect of PLL chain length on DNA binding efficiency and the physical properties of the resulting PLL/DNA polyplexes. The interaction of DNA and PLL molecules in 5 mm Hepes buffer (pH 7.0) (HB) was monitored based on the positive amino group (PLL) to negative phosphate group (DNA) charge ratio (NH 2 /PO 4 ratio). The PLL/DNA polyplexes that were generated using four different PLL chain lengths were analyzed for their particle size and potential (particle surface charge), as well as by agarose gel electrophoresis.
In the NH 2 /PO 4 ratio range of 0.25 to 1 (when the polyplex should theoretically be neutral), the size of the particle for each PLL chain length grew from approximately 95 to 105 nm with an increase in the amount of PLL (Figure 1a) . A further increase in the amount of PLL resulted in a decrease in particle size to approximately 40-80 nm. This was true for all PLLs tested except PLL 1116 , which showed reduced particle size at NH 2 /PO 4 ratios of 0.5 and higher. Analysis of the surface charge of the polyplexes showed that when the NH 2 /PO 4 ratio was increased from 0.25 to 1, the particles that were initially negatively charged at approximately −30 mV, became positively charged at 20 mV and remained in this charged state at higher NH 2 /PO 4 ratios (Figure 1b) .
One of the standards for measuring the degree of polyplex formation and charge neutralization, has been to perform agarose gel electrophoresis. 1, 12 When polyplexes were analyzed by this method, the DNA that was incubated with increasing amounts of PLL demonstrated charge neutralization at lower NH 2 /PO 4 ratios as the size of the PLL increased ( Figure 2) . Interestingly, when this is compared with potential analysis, this criteria for determining electroneutrality is very inaccurate. For example, when PLL 1116 was combined with DNA in an NH 2 /PO 4 ratio of 1:1 (Figure 2d, lane 4) , an electroneutral polyplex was generated. However, based on potential analysis, this same sample exhibits a charge of almost 20 mV (Figure 1b) . As a result, the measurement of electroneutrality by agarose gel electrophoresis for polyplex optimization is misleading and requires the use of more quantitative techniques such as potential analysis.
To determine whether the small size of PLL/DNA polyplexes that occur with PLL 1116 is actually beneficial for gene delivery, polyplexes made with each PLL were incubated with the cell line H1299 in the presence of chloroquine as an endosome release agent (Figure 3) . The results of this analysis showed that polyplexes made with PLL 1116 generated the highest level of gene transfer at all NH 2 /PO 4 ratios tested, while polyplexes made with PLL 19 showed the lowest level of gene transfer. This correlates well with particle size analysis and confirms that the small size of the polyplexes made with PLL 1116 does in fact aid in gene transfer.
To determine the effect of PLL chain length on particle formation and stability further, the PLL/DNA polyplexes formulated in HB were adjusted to a final NaCl concentration of 0.15 m since most physiological buffers, media and blood contain 0.1 to 0.15 m NaCl. When this was done, the particle size of PLL/DNA polyplexes made with PLL 19 , PLL 114 and PLL 244 greatly increased from approximately 40 nm to Ͼ200 nm ( Figure 4 ). When these polyplexes were incubated overnight at room temperature, the particle size increased even further to Ͼ500 nm ( Figure 4 ). In contrast, the polyplexes made with PLL 1116 showed a minimal change in size irrelevant of the condition used. These results suggest that PLL 1116 is capable of generating both smaller and more stable polyplexes for gene delivery, especially in buffers containing physiological salt. Modification of the PLL/DNA particle surface with soluble proteins Although there are several methods for attaching components to PLL/DNA polyplexes, we chose the streptavidin/biotin linkage system. This system provides several advantages: (1) biotinylation of proteins has been shown to be a safe method for modifying proteins while still maintaining protein function; 13 (2) the four biotin binding sites allow for the easy addition of multiple components to the polyplex; and (3) the addition of high molecular weight proteins such as streptavidin (SA), avidin (AV) and neutravidin (NA) (isoelectric points of 5, 10 and 6.8, respectively) can be used to measure the effect of these proteins on particle size and charge.
To determine the physical contribution of these proteins to PLL/DNA polyplex formation, the proteins were first attached to biotinylated PLL 114 at a protein/biotin ratio of 1:1 and then mixed with DNA at a NH 2 /PO 4 ratio of 1:1. PLL 114 was chosen for this analysis since the polyplexes formed with this PLL were not stable in either the presence or absence of NaCl. When negatively charged SA was added to the outside of the polyplex, the potential decreased while the positively charged AV increased the potential and the near neutral NA decreased the potential slightly (data not shown). Analysis of the PLL/DNA polyplexes coupled with these proteins in either HB or HBS showed that polyplexes having either SA or AV attached to the polyplex were more resistant to the effect of salt than polyplexes made with NA ( Figure 5 ). This can be seen by a minimal change in particle size for either AV/PLL/DNA or SA/PLL/DNA polyplexes while an increase in particle size from approximately 200 nm to Ͼ800 nm occurred for NA/PLL/DNA polyplexes ( Figure 5 ). As a result, the soluble proteins SA and AV are capable of stabilizing the interaction between PLL and DNA.
The effect of ligand on protein/DNA polyplex formation and gene delivery Based on the above PLL/DNA polyplex formulation results, we then attempted to connect a cell targeting ligand to the PLL/DNA polyplex through the linking protein, to test the effect of the ligand on particle size, particle charge and receptor-mediated gene transfer. In this analysis, SA was used as the linking protein, since it has lower nonspecific binding to cells than AV and contributes to overall particle stability. Epidermal growth factor, which is an acidic protein at neutral pH, was chosen as the cell targeting ligand since it is of small molecular weight and has applications for tumor cell targeting through EGF receptor overexpression on cancer cells. 14 To analyze the effect on particle charge, biotinylated EGF was stoichiometrically attached to the PLL/DNA polyplex by interacting with SA which was linked to biotinylated PLL (SA/biotin ratio, 1:1). Analysis of the potential for the PLL/DNA polyplexes formulated with PLLs of different chain length at each step of protein coupling clearly shows that both the negatively charged SA and EGF contributed to a decrease in the positive charge of the PLL/DNA polyplex ( Figure 6 ). The potential for the EGF/SA/PLL/DNA polyplex formulated with PLL 19 reached approximately −15 mV, whereas the potential for the EGF/SA/PLL/DNA polyplex formulated with PLL 1116 reached approximately 15 mV. This difference in potential for the polyplexes is due in part to the ratio of EGF to PLL in each polyplex which is at an EGF/PLL molar ratio of 0.6:1, 1.4:1, 0.9:1, 4.5:1 for PLL 19 and EGF/biotin ratios were both 1:1). However, PLL 1116 is 59 times longer than PLL 19 and when this difference is taken into account along with the ratio of biotin/PLL, the actual amount of EGF/polyplex at an EGF/SA ratio of 2:1 is 884 and 112 for PLL 19 and PLL 1116 , respectively, when equivalent amounts are used to achieve a NH 2 /PO 4 ratio of 1. As a result, there is approximately eight times less EGF on the polyplex made with PLL 1116 . This effect is also reflected in the analysis of particle size ( Figure 7) . As the number of EGF molecules on the polyplex was increased, the particle size for PLL 19 greatly increased. However, as the PLL chain length increased, there was a decrease in the effect on particle size as shown for PLL 1116 . While this is due in part to the number of EGF molecules on each polyplex (which is dependent upon the PLL chain length), this potentially indicates that spacing between the ligands on the outside of the polyplex is important since PLL 19 has approximately eight times more EGF per polyplex than PLL 1116 when equivalent amounts of the components and ratios are used.
To determine if ligand spacing or density affects particle size, PLL 1116 (which forms stable polyplexes when modified at 4.5 biotins/PLL) was modified to contain higher amounts of biotin per PLL molecule, allowing for an increase in the amount of EGF attached to each PLL molecule and the resulting polyplex. When polyplexes were made between DNA and PLLs containing 4.5, 11.7 and 34.5 biotin, little difference occurred in particle size (all polyplexes were approximately 100 nm in size), suggesting that this modification did not disrupt the ability to form PLL/DNA polyplexes (Figure 8a) . A similar observation occurred when SA was added to the PLL/DNA polyplex. However, the PLL 1116 containing Figure 8 The effect of ligand density on (a) (Figure 8a ). However, the greatest increase in size occurred for PLL 1116 containing 34.5 biotins (862 EGF per polyplex) as particle size increased to Ͼ1000 nm. This suggests that the spacing or density of the ligand on the outside of the complex can effect the size of the polyplex and that polyplexes containing greater than approximately 300 EGF molecules exhibit this effect. This situation is similar to that seen for PLL 19 , which in our analysis would have 884 EGF per polyplex (based on PLL/DNA = 1:1, biotin/PLL = 0.6:1, SA/biotin = 1:1 and EGF/SA = 2:1). This observation was further confirmed by performing uptake analysis of the EGF/DNA polyplexes on A431 cells (Figure 8b ). Since this system has not incorporated an endosomal bypass or release mechanism, replicationdefective adenovirus d1312 (MOI, 500) was used as an endosomal release agent by co-incubation with the polyplexes. 15 This MOI was used to minimize toxicity during transduction analysis. Staining of the cells for ␤-gal expression indicated that efficient uptake occurred with polyplexes made with PLL of 4.5 and 11.7 biotins. However, little or no uptake occurred when PLL containing 34.5 biotins was used.
To determine if combining PLL 1116 (with 4.5 biotins), SA and Ͻ300 EGFs into a polyplex with DNA results in the most efficient uptake (based on the ability of these components to maintain small particle size), polyplexes made with the four different PLLs were incubated with the cell line A431 along with dl312 as an endosomal release agent (Figure 9 ). Staining of the cells for ␤-gal expression indicated that polyplexes made with PLL 1116 generated the highest level of uptake (up to 30%). This confirms that much smaller and more stable polyplexes can be made with PLL 1116 , SA and Ͻ300 EGF per poly-
Figure 9 Gene delivery efficiency of PLL/DNA polyplexes prepared with PLLs of different chain lengths and coupled to SA and EGF. The NH 2 /PO 4 ratio and the SA/biotin molar ratio was 1:1, while the SA to EGF molar ratio was 2:1. The competition with free EGF was done at either a 50-fold or 100-fold molar excess to EGF attached to the polyplex. Competition with insulin was done at a 200-fold molar excess to EGF attached to the polyplex. The percentage of blue-staining cells represents the number of cells staining positive for gene expression.
plex than with smaller versions of PLL. Also, to ensure that this was due to specific uptake through the EGF receptor and not through nonspecific uptake by the adenovirus receptor, competition with free EGF was performed ( Figure 9) . A slight reduction (5%) could be achieved with a 50-fold molar excess of free EGF. However, a much higher level of reduction (60%) occurred when a 100-fold molar excess of free EGF was used. To ensure that this competition was not simply due to free EGF competing with a nonspecific binding of adenovirus to the EGF/DNA polyplex, competition was also performed with insulin as a nonspecific competitor (Figure 9 ). When a 200-fold molar excess of insulin (which is similar in size to EGF) was used, there was no decrease in the number of cells transduced, indicating that the competition using free EGF occurs specifically between EGF attached to the polyplex and free EGF and not with adenovirus interacting with the polyplex. Overall, these studies have identified that PLL 1116 when coupled to a low number of EGF molecules (Ͻ300 at an EGF/SA of 2:1) in combination with SA, generates a polyplex that is smaller and more efficient for gene delivery than polyplexes made with shorter chain PLLs and higher amounts of EGF.
Discussion
Receptor-mediated gene transfer methods using polycations such as PLL have employed both different methods and sizes of PLL to induce DNA condensation. [1] [2] [3] [4] [5] [6] [7] [8] 11, 12 A recent study by Wolfert and Seymour 11 identified that long chain PLL (average MW, 224.5 kDa) is not as efficient in complexing DNA as shorter versions of PLL. However, by using a NH 2 /PO 4 ratio of up to 12, carrying out the reaction in pure water, and measuring the particle size in a solid state, these experimental conditions are far from in vitro and in vitro situations. In our analysis, the effect of PLL chain length on DNA condensation efficiency (particle charge and particle size) were examined in a more practical environment, using solutions containing physiological salt (NaCl, 0.15 m). Although all PLLs showed essentially the same characteristics in terms of particle size and particle charge, PLL 1116 was slightly better at forming small polyplexes. However, the major differences occurred when these polyplexes were transferred into solutions containing 0.15 m NaCl and after an overnight incubation at room temperature. In these conditions, PLL 1116 was much better at forming smaller and more stable polyplexes than shorter PLLs, such as PLL 19 .
Zeta potential analysis of these polyplexes identified that there was relatively no difference in particle charge of polyplexes made with different-sized PLLs. This analysis was also done on polyplexes in physiological salt and showed that the surface charge of the polyplexes disappeared (data not shown). This indicates that the strong small molecule electrolytes (Na + , Cl − ) balanced the particle surface charge which resulted in aggregation and precipitation for the polyplexes made with PLL 19 , PLL 114 and PLL 244 . Based on particle size analysis, this salt effect became smaller as the PLL chain length increased and had a minimal effect on polyplexes made with PLL 1116 , indicating that the binding of longer chain PLL to DNA molecules occurs at a higher affinity than shorter versions of PLL. This would suggest that the longer the chain length of PLL, the greater the ability of the PLL molecule to form longer regions of thermodynamically stable binding between PLL and DNA.
Further stabilization was achieved by adding the proteins SA or AV to the outside of the polyplex. Since NA, which has a neutral charge, was incapable of stabilization, this suggests that the charge of SA and AV contributed to this effect. As a result, the proteins may be forming a shell around the polyplex that protects against the strong small molecule electrolytes. The stabilization of the PLL/DNA polyplexes by higher molecular weight proteins, may be similar to targeted gene delivery vectors that have used large proteins as ligands. [1] [2] [3] [4] 8 Initial work by Wu et al 1 used ASOR (MW, 40 000) in combination with PLL of small molecular weight to generate an ASOR/PLL conjugate which resulted in highly efficient gene delivery. More recently, Plank et al 10 used derivatives of polyethylene glycol to change the interaction of polyplexes with complement proteins and thus potentially lending a certain degree of stability to the polyplex.
The addition of the targeting ligand EGF to the polyplex generated an opposite effect as compared with SA or AV. As more EGF was added to the polyplex, greater destabilization occurred and an increase in particle size resulted. This was primarily seen with PLL 19 while little change occurred for PLL 114 , PLL 244 and PLL 1116 . Based on particle charge analysis, this effect seems to be due to a charge contribution since EGF has a high negative charge (IP, 3). However, a small number of EGF molecules did not affect the SA shelling of the PLL/DNA polyplex made with PLL 19 , while a higher number of EGF molecules (calculated to be 442, 884, 1326 EGF molecules per polyplex at EGF/SA ratio of 1:1, 2:1, and 3:1) did interfere with not only the interaction between PLL and DNA by a charge contribution, but also through possible steric hindrance of adjacent EGF molecules. This effect was confirmed by the use of PLL 1116 containing 34.5 biotin as compared with PLL 1116 containing 4.5 and 11.7 biotin. The number of EGF molecules per polyplex at a 1:1, 2:1, and 3:1 ratio with PLL 1116 containing 34.5 biotins, is 431, 862 and 1293. These amounts are very close to those that result when PLL 19 (modified to contain 0.6 biotin per PLL) was used. The polyplexes generated with PLL 1116 containing 34.5 biotins showed similar particle size and gene delivery efficiencies as those made with PLL 19 . As a result, the efficiency with which the polyplexes are able to form may be due to a critical number of molecules that can be added to PLL before interaction between adjacent EGF molecules occurs. If neighboring EGFs are interacting with each other, then possible steric hindrance may destabilize the polyplex. It is also possible that the biotinylated PLL could have had a reduced binding affinity for DNA because of the degree of modification. However, particle size analysis of the PLL/DNA complexes did not reflect this point.
When all of these components (PLL 1116 , SA, and Ͻ300 EGFs per polyplex) were used in PLL/DNA polyplex formation, the resulting uptake efficiency was greatest in this polyplex as compared with those made with smaller PLLs and with higher amounts of EGF. These polyplexes were aided in their release from the endosomal compartment by dl312. However, there was very little contribution of the adenovirus to the uptake process as seen by the ability to compete EGF/DNA polyplex transduction with free EGF. The limited contribution of adenovirus to the interaction of a ligand with its receptor has been shown by other groups as well. 15 Since we are focusing on the development of 'synthetic viruses', the components of the polyplex that we have used thus far are similar in function to proteins that are used in adenovirus formation. The function of PLL 1116 to bind and compact DNA, the addition of SA to the polyplex to form a protective shell, and the use of EGF as a targeting ligand, mirror the function of the arginine/alanine-rich core of the adenovirus, the adenovirus hexon protein, and the ligand associated with the fiber protein respectively. [16] [17] [18] The use of the SA/biotin interaction, also allows for the EGF to be in a structural confirmation similar to the fiber protein, ie projected away from the polyplex. Although we have not included a protein to replace the function of the penton base, we have generated the basis for the incorporation of a protein or peptide with this function into the polyplex, allowing for its contribution to both polyplex charge and size.
Unfortunately, one of the limiting factors associated with this system is the complexity involved which is seen by the number of components that are required for efficient gene delivery. It is possible that some of these components could be combined into one agent. An example of such an agent is polyethylenimine. 19 This branched chain polymer can function as a DNA-binding agent, a linking agent for a ligand, and because of its ability to act as a 'proton sponge', an endosome bypass agent as well. Further analysis of polyplexes and their formation may allow for other components to be combined as well.
We have identified from these studies that PLL 1116 can bind DNA to form more stable polyplexes at low NH 2 /PO 4 ratios and that this stability can be increased by using proteins such as SA, that provide a favorable charge shell around the polyplex, making it less sensitive to changes in the surrounding environment, ie salt conditions. Small ligands such as EGF have a great effect on the surface charge of the polyplex and longer chain PLLs are less sensitive to this effect because of the higher binding affinity to DNA. While the charge of the ligand affects polyplex formation, it is in fact the number of ligands per each chain of PLL (and the resulting number on the polyplex) that has a greater effect on the stabilization of the polyplex. This probably occurs through interactions between adjacent molecules by increasing steric hindrance and contributing to the repulsive forces of the charge interaction between DNA and PLL. These data indicate that the generation of polyplex-based systems is a complex process, and now provides the basis for the addition of proteins or peptides of various function, charge and size on to the polyplex, allowing for improved polyplex formation and gene delivery. These findings also have direct applications to systems based on the use of molecular conjugates that are derived from the coupling of ligands to PLL, as well as other polycations. Poly-l-lysine has recently been used in other nonviral vectors such as lipoplexes in which the PLL acts to compact DNA, as well as allowing for interactions with the lipid. 20 The optimization of the interaction between PLL and DNA as we have shown here will also be crucial for the development of these vectors. Just as important to the development of these vectors will be the coupling strategy and ligand. In terms of using SA/biotin for coupling, while this may not be the final strategy used for conjugate formation, our studies using this system have identified that there are important contributions of proteins such as SA and the ligand to polyplex formation making these studies critical to the further development of nonviral vectors.
Materials and methods

Materials
Human recombinant epidermal growth factor (EGF) was purchased from BioSource International (Camarillo, CA, USA). Poly-l-lysine with average chain lengths of 19, 114, 244, 1116 (average molecular weight, 3.97, 23.8, 51.0 and 233.2 kDa, respectively) as hydrobromide salts, fluorescamine, insulin, chloroquine, and glycine were purchased from Sigma (St Louis, MO, USA) streptavidin (SA), avidin (AV), neutravidin (NA), NHS-SS-biotin (sulfosuccinimidyl 2-(biotinamido)ethyl-1,3-dithioproprionate), HABA dye (2-(4Ј-hydroxyazo-benzene) benzoic acid), Traut's reagent (2-iminothiolane-HCl), Ellman's reagent (5,5Ј-dithio-bis-(2-nitrobenzoic acid)), and cysteine-HCL monohydrate were purchased from Pierce (Rockford, IL, USA).
Plasmid DNA
The plasmid pCMV/␤-Gal, which contains the Escherichia coli ␤-galactosidase gene under the control of the cytomegalovirus enhancer and promoter was used in polyplex formation and transduction studies. The plasmid was purified using a Nucleobond Ax DNA Maxi-Prep Kit (Nest Group, Southboro, MA, USA) (which also included a step to remove contaminating endotoxin) according to the manufacturer's instructions. The purity was confirmed by electrophoresis through a 1% agarose gel, as visualized by ethidium bromide staining.
Preparation of molecular conjugates and protein/DNA polyplexes Biotinylation and characterization of EGF/biotin: Two milligrams of EGF (MW, 6 kDa) was dissolved in 1 ml KHPO 4 (pH 7.0). One milligram NHS-SS-biotin (MW, 606.5) was added directly into the EGF solution, then incubated at room temperature for 1 h. The sample was then desalted on a BioRad P6-DG (1.5 × 15 cm) column (20 mm KHPO 4 (pH 7.0), 100 mm NaCl as eluant), dialyzed (MW cut-off, 1000 Da) against H 2 O at 4°C, and then lyophilized. The lyophilized sample was resuspended in Hepes buffered saline (HBS) (20 mm Hepes pH 7.0, 150 mm NaCl) with 50% glycerol and stored at −80°C until used. Protein concentration was determined by the BioRad protein assay (BioRad, Hercules, CA, USA) and the BCA protein assay (Pierce). The number of biotins attached to EGF was determined by the HABA assay. 21 The resulting molar ratio of biotin:EGF was routinely 1.2:1.
Biotinylation and characterization of PLL/biotin: One hundred milligrams of PLL was dissolved in 2 ml of 100 mm KHPO 4 (pH 7.0). Five molecular equivalent of NHS-SSbiotin (MW, 606.5) were then added directly to the PLL solution with stirring and then incubated at room temperature for 1 h. The reaction mixture was desalted as before, dialyzed (MW cut-off, 1000 Da) against H 2 O (three changes) at 4°C for 24 h, lyophilized, and then resuspended in HBS. The concentration of the biotinylated PLL was determined by the concentration of primary amines on PLL and their average molecular weight using a fluorescamine-based assay. 22, 23 The concentration of attached biotin was analyzed by the HABA assay. The four PLLs with average chain lengths of 19, 114, 244 and 1116 amino groups were modified to contain biotin at a biotin:PLL molecular ratio of 0.6:1, 1.4:1, 0.9:1 and 4.5:1, respectively.
Coupling of biotinylated EGF to biotinylated PLL: The interaction between EGF-biotin and PLL/biotin is based on the well-established avidin-biotin chemistry in that AV, SA and NA each have four binding sites for biotin, therefore, the EGF and PLL are connected via this interaction. 9 The stoichiometric biotin-avidin reaction was based on the concentration of the linking protein and the concentration of biotin on the biotinylated EGF or biotinylated PLL. This reaction was typically carried out in 5 mm Hepes buffer (pH 7.0) (HB) by a dropwise addition of the EGF/biotin to either SA, AV or NA with vortexing. After a 5-min incubation at room temperature, the PLL/biotin was added dropwise to the EGF/biotin/SA reaction mixture with vortexing and then incubated at room temperature for 5 min. The resulting EGF/SA/PLL conjugate was then used for polyplex formation.
Polyplex formation and DNA delivery Polyplex formation consisted of a dropwise addition of plasmid (final concentration, 10 g/ml) in 5 mm HB to the appropriate sample, ie PLL, SA/PLL or EGF/SA/PLL in HB with vortexing. The final reaction was incubated for 30 min at room temperature and then analyzed either for particle size, particle charge or gene delivery. The cell lines used in this study to analyze gene delivery were H1299 (human large cell lung adenocarcinoma, gift of Drs Adi Gazdar and John Minna) and A431 (human epidermoid carcinoma) (ATCC, Rockville, MD, USA) which expresses EGF receptors at 2 × 10 6 EGF receptors per cell. 24 Cells were plated in six-well plates (Falcon Plastics, Oxnard, CA, USA) in the appropriate medium 48 h before incubation in quantities sufficient to give a confluency of 60-70% at the time of use. All incubations of the polyplexes with cells were done in 1 ml of normal cell culture medium with 2% fetal calf serum along with either replication-defective adenovirus dl312 (MOI, 500) or chloroquine (50 m) at 37°C in a CO 2 incubator for 2 h followed by the addition of 2 ml of complete media. Following a 24-h incubation, cells were stained histochemically for ␤-gal expression.
Particle size and potential measurement The particle size and potential of all polyplexes made with DNA was measured on a N4+ particle size analyzer (Coulter, Miami, FL, USA) and a DELSA 440SX electrophoretic mobility analyzer (Coulter), respectively. Measurements were done in either HB or HBS with a DNA concentration of 10 g/ml at 25°C. The polyplex formation was allowed to proceed for 30 min at room temperature and then data measured for particle size was collected at a 90°angle and processed using both unimodel and size distribution process (SDP) analysis. The data for potential was collected at four angles (8.9°, 17.6°, 26.3°, 35.2°) simultaneously and at two stationary layer positions. Samples containing DNA were measured 20 times for 60 s at a frequency range of 250 Hz and a cell field of 15V/cm. The automatic calculation is based on the electrophoretic mobility.
Statistical analysis
All results are presented as the mean ± standard deviation. Experiments were performed with duplicate or triplicate samples and the results of at least two experiments were used in the generation of statistically accurate data.
